Abstract
Dengue virus infection causes dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS), whose pathogeneses are not clearly understood. Current hypotheses of antibody-dependent enhancement, virus virulence, and IFN-γ/TNFα-mediated immunopathogenesis are insufficient to explain clinical manifestations of DHF/DSS such as thrombocytopenia and hemoconcentration. Dengue virus infection induces transient immune aberrant activation of CD4/CD8 ratio inversion and cytokine overproduction, and infection of endothelial cells and hepatocytes causes apoptosis and dysfunction of these cells. The coagulation and fibrinolysis systems are also activated after dengue virus infection. We propose a new hypothesis for the immunopathogenesis for dengue virus infection. The aberrant immune responses not only impair the immune response to clear the virus, but also result in overproduction of cytokines that affect monocytes, endothelial cells, and hepatocytes. Platelets are destroyed by crossreactive anti-platelet autoantibodies. Dengue-virus-induced vasculopathy and coagulopathy must be involved in the pathogenesis of hemorrhage, and the unbalance between coagulation and fibrinolysis activation increases the likelihood of severe hemorrhage in DHF/DSS. Hemostasis is maintained unless the dysregulation of coagulation and fibrinolysis persists. The overproduced IL-6 might play a crucial role in the enhanced production of anti-platelet or anti-endothelial cell autoantibodies, elevated levels of tPA, as well as a deficiency in coagulation. Capillary leakage is triggered by the dengue virus itself or by antibodies to its antigens. This immunopathogenesis of DHF/DSS can account for specific characteristics of clinical, pathologic, and epidemiological observations in dengue virus infection.
Article PDF
Similar content being viewed by others
References
An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology 263:70–77;1999.
Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 161:6338–6346;1998.
Bachmann F, Kruithof EKO. Tissue plasminogen activator: Chemical and physiological aspects. Semin Thromb Hemost 10:6–17;1984.
Bhamarapravati N. Hemostatic defects in dengue haemorrhagic fever. J Infect Dis (suppl 4):S826–S829;1989.
Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 18(suppl 2) 2:44–47;2000.
Bhamarapravati N, Tuchinda P, Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: A study of 100 autopsy cases. Ann Trop Med Parasitol 61:500–510;1967.
Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvei A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK53): Clinical, immunological and biological responses in adult volunteers. Bull WHO 65:189–195;1987.
Bielefeldt-Ohmann H. Pathogenesis of dengue virus diseases: Missing pieces in the jigsaw. Trends Microbiol 5:409–413;1997.
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol 17:189–220;1999.
Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infection in Bangkok. Am J Trop Med Hyg 38:172–180;1988.
Cardosa MJ. Dengue vaccine design: Issues and challenges. Br Med Bull 54:395–405;1998.
Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, Hack CE. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 90:1501–1507;1997.
Falconar AKI. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. Arch Virol 142:897–916;1997.
Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, Kurane I, Rothman AL, Ennis FA. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis 180:1429–1435;1999.
Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Lew R, Innins B, Kurane I, Rothman AL, Ennis FA. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179:755–762;1999.
Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Rothman AL, Ennis FA. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 59:329–334;1999.
Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74:5477–5485;2000.
Halstead SB. Observations related to the pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42:350–362;1970.
Halstead SB. Pathogenesis of dengue: Challenge to molecular biology. Science 239:476–481;1988.
Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkey. I. Clinical laboratory responses to primary infection. J Infect Dis 128:7–14;1973.
Heegaard ED, Rosthoj S, Petersen BL, Nielsen S, Karup Pedersen F, Hornsleth A. Role of parvovirus B19 infection in childhood idiopathic thrombocytopenic purpura. Acta Paediatr 88:614–617;1999.
Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 3:376–396;1990.
Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Lai JH. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 166:1499–1506;2001.
Huang KJ, Li SYJ, Chen SC, Liu HS, Lin YS, Yeh TM, Liu CC, Lei HY. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol 81:2177–2182;2000.
Huang YH. Study on the mechanism of hemorrhage induced by dengue virus infection; thesis. Tainan, National Cheng Kung University, 2000.
Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yeh TM. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol 110:35–40;1997.
Huang YH, Lei HY, Lin YS, Chen SH, Liu HS, Liu CC, Yeh TM. Dengue virus infection induces endothelial cell damage by both direct and indirect manners, submitted.
Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, Chen SH, Yeh TM. Tissue plasminogen activator of human endothelial cells induced by dengue virus infection is IL-6 dependent, submitted.
Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, Yeh TM. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Am J Tropic Med Hyg 63:71–75;2001.
Huang YH, Liu CC, Wang ST, Lei HY, Liu HS, Lin YS, Wu HL, Yeh TM. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol 63:247–251;2001.
Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol 73:783–786;1999.
Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, Kunentrasai N, Viramitrachai W, Ratanachueke S, Kiatpolpoj S, Innis BL, Rothman AL, Nisalak A, Ennis FA. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 176:313–321;1997.
Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38:411–419;1988.
Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever in infants. Am J Trop Med Hyg 40:444–451;1989.
Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, Phillips IA, Ewing DF, Murphy GS, Porter KR. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 18:3166–3173;2000.
Kurane I, Ennis FA. Immunity and immunopathology in dengue virus infections. Semin Immunol 4:121–127;1992.
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA. High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg 48:222–229;1993.
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA. Activation of T-lymphocytes in dengue virus infection. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 88:1473–1480;1991.
Kurane I, Janus J, Ennis FA. Dengue virus infection of human skin fibroblasts in vitro production of IFN-β, IL-6 and GM-CSF. Arch Virol 124:21–30;1992.
La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillières Clin Haematol 8:249–270;1995.
Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, deChacon Ramos C, Rico-Hesse R. Dengue virus structural difference that correlates with pathogenesis. J Virol 73:4738–4747;1999.
Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 63:143–149;2001.
Lin YL, Lei HY, Wen YY, Luh TY, Chou CK, Liu HS. Light-independent inactivation of dengue-2 virus by carboxyfullerene C3 isomer. Virology 275:258–262;2000.
Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, Kao CL, King CC. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 72:9729–9737;1998.
Lin YL, Liu CC, Lei HY, Yeh TM, Lin YS, Chen RMY, Liu HS. Infection of five human liver cell lines by dengue-2 virus. J Med Virol 60:425–431;2000.
Lin YL, Liu CC, Chuang JI, Lei HY, Yeh TM, Lin YS, Huang YH, Liu HS. Involvement of oxidative stress, NF-IL-6 and RANTES expression in dengue-2 virus infected human liver cells. Virology 276:114–126;2000.
Liu CC, Huang KJ, Lin YS, Yeh TM, Liu HS, Lei HY. Transient CD4/CD8 ratio inversion and immune deviation during dengue virus infection, submitted.
Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 80:2956–2960;1983.
Lucia B, Jennings C, Cauda R, Ortona L, Landay AL. Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry 22:10–15;1995.
Mathew A, Kurane I, Green S, Vaughn DW, Kalayanarooj S, Suntayakorn S, Ennis FA, Rothman AL. Impaired T cell proliferation in acute dengue infection. J Immunol 162:5609–5615;1999.
Meiklejohn G, England B, Lennette EH. Adaptation of dengue virus strains in unweaned mice. Am J Trop Med Hyg 1:51–58;1952.
Miller SC, Kearney SL. Effect of in vivo administration of all trans-retinoic acid on the hemopoietic cell populations of the spleen and bone marrow: Profound strain differences between A/J and C57BL/6j mice. Lab Anim Sci 48:74–80;1998.
Mohan B, Patwari AK, Anand VK. Hepatic dysfunction in childhood dengue infection. J Trop Pediatr 46:40–43;2000.
Nimmannitya S. Clinical spectrum and management of dengue hemorrhagic fever. Southeast Asian J Trop Med Publ Health 3:392–397;1987.
Pacsa AS, Agarwal R, Elbishbishi EA, Chaturvedi UC, Nagar R, Mustafa AS. Role of interleukin-12 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 28:151–155;2000.
Qu X, Chen W, Maguire T, Austin F. Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system. J Gen Virol 74:89–97;1993.
Raut CG, Deolankar RP, Kolhapure RM, Goverdhan MK. Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol 40:143–146;1996.
Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 81:1659–1667;2000.
Rico-Hesse R, Harrison L, Nisalak A, Vaugh DW, Kalayanarooj S, Green S, Rothman AL, Ennis FA. Molecular evolution of dengue type 2 virus in Thailand. Am J Trop Med Hyg 58:96–101;1998.
Rico-Hesse R, Harrison L, Salas R, Tovar D, Nisalak A, Ramos C, Boshell J, Rde Mesa M, Nogueira R, Travassos da Rosa A. Origins of dengue 2 viruses associated with increased pathogenicity in the Americas. Virology 230:244–251;1997.
Rosen L. The emperor's new clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am J Trop Med Hyg 26:337–343;1977.
Rosen L, Khin MM, U T. Recovery of virus from the liver of children with fatal dengue: Reflection on the pathogenesis of the disease and its possible analogy with that of yellow fever. Res Virol 140:351–360;1989.
Rothman AL, Ennis FA. Immunopathogenesis of dengue hemorrhagic fever. Virol 257:1–6;1999.
Surveillance Report Monthly. Taipei: National Health Administration, Executive Yuan, Republic of China, 15:14–18;1999.
Tsao N, Kanakamma PP, Luh TY, Chou CK, Lei HY. The inhibition ofEscherichia coli-induced meningitis by carboxyfullerence. Antimicrob Agents Chemother 43:2273–2277;1999.
van der Most RG, Murali-Krishna K, Asmed R, Strauss JH. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: Quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74:8094–8101;2000.
Van Gorp ECM, Shuarti C, ten Cate H, Dolmans WMV, van der Meer JWM, ten Cate JW, Brandjes DPM. Review: Infectious diseases and coagulation disorders. J Infect Dis 180:176–186;1999.
Vaughn DW. Invited commentary: Dengue lessons from Cuba. Am J Epidemiol 152:800–803;2000.
Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with severity. J Infect Dis 181:2–9;2000.
Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Rothman AL, Ennis FA, Nisalak A. Dengue in the early febril phase: Viremia and antibody responses. J Infect Dis 176:322–330;1997.
Wang S, He R, Patarapotikul J, Innis BL, Anderson R. Antibody-enhanced binding of dengue-2 virus to human platelets. Virology 213:254–257;1995.
Whyte AL, Miller SC. Strain differences in natural killer cell-mediated immunity among mice: A possible mechanism for the low natural killer cell activity of A/J mice. Immunobiology 199:23–38;1998.
WHO. Dengue haemorrhagic fever: Diagnosis, treatment and control. Geneva, World Health Organization, 1986.
WHO. Dengue haemorrhagic fever: Diagnosis, treatment and control. Geneva, World Health Organization, 1997.
Wu SJL, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6:816–820;2000.
Yadav M, Kamath KR, Iyngkaran N, Sinniah M. Dengue haemorrhagic fever and dengue shock syndrome: Are they tumor necrosis factor-mediated disorders? FEMS Microbiol Immunol 4:45–49;1991.
Yoto Y, Kudoh T, Suzuki N, Katoh S, Matsunaga Y, Chiba S. Thrombocytopenia induced by human parvovirus B19 infections. Eur J Haematol 50:255–257;1993.
Zhang YM, Hayes EP, McCarty TC, Dubois DR, Summers PL, Eckels KH, Chanock RM, Lai CJ. Immunization of mice with dengue structural proteins and nonstructural proteins NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J Virol 62:3027–3031;1988.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lei, HY., Yeh, TM., Liu, HS. et al. Immunopathogenesis of dengue virus infection. J Biomed Sci 8, 377–388 (2001). https://doi.org/10.1007/BF02255946
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02255946